MA-EXAGRID
28.5.2019 17:41:10 CEST | Business Wire | Press release
ExaGrid ® , a leading provider of intelligent hyperconverged storage for backup, today announced that Physicians’ Reciprocal Insurers (PRI) uses ExaGrid disk-based backup systems to significantly increase data protection with secure backups.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190528005580/en/
PRI is a leading provider of professional liability insurance for physicians and medical facilities. As the second largest medical malpractice insurer in New York State and one of the top ten in the U.S., PRI is recognized as one of the most respected names in its field.
PRI replaced its previous system with ExaGrid and Veeam after its IT staff spent too much time troubleshooting backup issues. Al Villani, PRI’s senior system administrator said, “Veritas NetBackup wasn’t set up to send us any kind of alerts if there was an issue, so we had to log in and look through it, which was a lot of manual work. Our calls to Symantec support were sent offshore right away, and by the time they got back to us, we had usually found the solution by searching online. Veritas eventually reacquired NetBackup, but the support never improved.”
ExaGrid solved backup issues PRI had struggled with, including:
- Storage capacity issues
- Backups that exceeded window, slowing company-wide systems during workday
- Time-consuming backup management
- Complicated offsite storage
The security of data storage in the insurance industry has been moving toward stricter regulation, so PRI looked for a solution that would help keep the company ahead of the curve. “The insurance claims we process contain sensitive information, such as birth dates and Social Security numbers—even the tape we used was encrypted, the cases we stored them in were locked, and Iron Mountain had to sign for them—the state regulations are pretty thorough when it comes to security. Many solutions don’t offer encryption or the ability to encrypt at rest like ExaGrid does,” said Villani.
A major issue that PRI faced was that its backups took days and slowed the entire system down, impacting workflow. “Our weekly full backup used to run from Saturday morning at 2:00 a.m. all the way into Tuesday afternoon. Every Monday, users would be calling in and asking why the system was so slow. Now, our weekly full takes just three hours! We thought something was broken the first time we used ExaGrid, so we called our support engineer who confirmed that everything ran correctly. It’s totally incredible! Working with our [ExaGrid] support engineer has been a saving grace. Managing backups had been a nightmare at times, but switching to ExaGrid has been a dream come true. We’re saving about 25-30 hours a week on managing backups. The ExaGrid system doesn’t need a lot of babysitting, and our support engineer is available whenever we need help with any issue.”
As an insurance company, PRI has a complex retention policy for its data. “We keep five weeks of daily backups, eight weeks of weekly backups, a year’s worth of monthly backups onsite, and one yearly onsite with seven yearlies offsite, as well as offsite storage for infinite fiscals and monthly backups,” said Villani. “We were skeptical at first that an ExaGrid system could handle that amount of storage, but the engineers sized everything really well and ExaGrid guaranteed the sizing would work for two years, and that if we needed to add another appliance, they would supply it. Seeing that in writing was pretty impressive!”
Read the complete PRI customer success story to learn more about the company’s experience using ExaGrid.
ExaGrid’s published customer success stories and enterprise stories number over 360, more than all other vendors in the space combined. These stories demonstrate how satisfied customers are with ExaGrid’s unique architectural approach, differentiated product, and unrivalled customer support. Customers consistently state that not only is the product best-in-class, but ‘it just works.’
About ExaGrid
ExaGrid provides intelligent hyperconverged
storage for backup with data deduplication, a unique landing zone, and
scale-out architecture. ExaGrid’s landing zone provides for the fastest
backups, restores, and instant VM recoveries. Its scale-out architecture
includes full appliances in a scale-out system and ensures a
fixed-length backup window as data grows, eliminating expensive forklift
upgrades. Visit us at exagrid.com
or
connect with us on LinkedIn
.
See what our customers have to say about their own ExaGrid experiences
and why they now spend significantly less time on backup.
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190528005580/en/
Contact:
Stacey Foster ExaGrid sfoster@exagrid.com 508-898-2872 x0248
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
